Quantcast
Channel: DR ANTHONY MELVIN CRASTO Ph.D – New Drug Approvals
Viewing all articles
Browse latest Browse all 1718

Perfluorhexyloctane

$
0
0

WeightAverage: 432.269
Monoisotopic: 432.112266666Chemical FormulaC14H17F13

Perfluorhexyloctane

  • 133331-77-8
  • MIEBO
  • Tetradecane, 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoro-
  • 7VYX4ELWQM
  • NOV03, NOV 03
  • 1-(perfluorohexyl)octane
  • F6H8
  • NOV03
  • Perfluorohexyloctane

1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane

FDA APPROVED 8/16/2023, Sohonos, To reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva
Drug Trials Snapshot

Perfluorohexyloctane is a fluoroalkane that is tetradecane in which all of the hydrogen atoms at positions 1, 2, 3, 4, 5, and 6 have been replaced by fluorine atoms. It is an ophthalmic solution used to treat the signs and symptoms of dry eye disease. It has a role as an ophthalmology drug and a nonionic surfactant. It is a fluorohydrocarbon and a fluoroalkane. It derives from a hydride of a tetradecane.

Perfluorohexyloctane (branded as EvotearsMiebo,[a] and Novatears, among others) is a medication used for the treatment of dry eye disease.[4] It is a semifluorinated alkane.[4]

Perfluorohexyloctane has been available in multiple markets since 2015 under the brand names Evotears and Novatears,[5] and was additionally approved for medical use in the United States in May 2023 under the brand name Miebo.[4][6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7]

PATENT

Show 102550100 entries

Patent NumberPediatric ExtensionApprovedExpires (estimated)
US11357738No2022-06-142036-09-29US flag
US10058615No2018-08-282033-09-12US flag
US10369117No2019-08-062033-09-12US flag
US10449164No2019-10-222033-09-12US flag
US10507132No2019-12-172037-06-21US flag
US10576154No2020-03-032033-09-12US flag

SYN

https://www.scientificupdate.com/process-chemistry-articles/not-a-dry-eye-in-the-house

Medical uses

Perfluorohexyloctane is indicated for the treatment of the signs and symptoms of dry eye disease.[4][8][9]

Availability

Perfluorohexyloctane is sold as an over-the-counter medication under the brand names Evotears and Novatears in multiple countries,[10] costing around NZ$34.00, A$30, and €30 for a one-month supply.

In the US, perfluorohexyloctane is sold under the brand name Miebo; a prescription is required.

Notes and references

  1. ^ /ˈmaɪboʊ/ MY-bow
  1. ^ “Notice: Multiple additions to the Prescription Drug List (PDL) [2024-10-18]”Health Canada. 18 October 2024. Retrieved 25 October 2024.
  2. ^ “Miebo product information”Health Canada. 4 September 2024. Retrieved 27 December 2024.
  3. ^ “Regulatory Decision Summary for Miebo”Drug and Health Products Portal. 4 September 2024. Retrieved 27 December 2024.
  4. Jump up to:a b c d e “Miebo- perfluorohexyloctane solution”DailyMed. 18 May 2023. Retrieved 8 June 2023.
  5. ^ “URSAPHARM GmbH and Novaliq GmbH Announce European Partnership Agreement” (Press release). Retrieved 15 February 2024.
  6. ^ “Bausch + Lomb and Novaliq Announce FDA Approval of Miebo (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease” (Press release). Bausch + Lomb Corporation. 18 May 2023. Retrieved 8 June 2023 – via Business Wire.
  7. ^ New Drug Therapy Approvals 2023 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 10 January 2024. Retrieved 9 January 2024.
  8. ^ Ballesteros-Sánchez A, De-Hita-Cantalejo C, Sánchez-González MC, Jansone-Langine Z, de Sotomayor MA, Culig J, et al. (October 2023). “Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent”. The Ocular Surface30: 254–262. doi:10.1016/j.jtos.2023.10.001hdl:11441/151762PMID 37813152S2CID 263802332.
  9. ^ Sheppard JD, Evans DG, Protzko EE (November 2023). “A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solution”The American Journal of Managed Care29 (14 Suppl): S251 – S259. doi:10.37765/ajmc.2023.89464PMID 37930231S2CID 265032840.
  10. ^ “In Australia, NovaTears Eye Drops Are Available on the Pharmaceutical Benefits Scheme (PBS) from Now On” (Press release). Retrieved 15 February 2024.

Further reading

Clinical data
Trade namesEvotears
Miebo (/ˈmaɪboʊ/ MY-bow)
Novatears
Other namesNOV03; 1-(perfluorohexyl)octane
AHFS/Drugs.comMonograph
MedlinePlusa623054
License dataUS DailyMedPerfluorohexyloctane
Routes of
administration
Eye drops
ATC codeNone
Legal status
Legal statusCA℞-only[1][2][3]US: ℞-only[4]
Identifiers
showIUPAC name
CAS Number133331-77-8
PubChem CID10477896
DrugBankDB17823
ChemSpider8653305
UNII7VYX4ELWQM
KEGGD12604
ChEBICHEBI:229658
CompTox Dashboard (EPA)DTXSID20440585 
Chemical and physical data
FormulaC14H17F13
Molar mass432.269 g·mol−1
3D model (JSmol)Interactive image
showSMILES
showInChI

////////Perfluorhexyloctane, Sohonos, APPROVALS 2023, FDA 2023, NOV03, NOV 03, MIEBO, 1-perfluorohexyl)octane, F6H8, NOV03, Perfluorohexyloctane


Viewing all articles
Browse latest Browse all 1718

Trending Articles